Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vaso ( (VASO) ) has shared an update.
On November 19, 2025, Vaso Corporation announced its agreement to sell its subsidiary, VasoHealthcare IT Corp, to Nano-X Imaging Ltd. This decision follows a strategic review aimed at focusing on Vaso’s core operations. VasoHealthcare IT, a healthcare IT application reseller, contributes less than 5% of Vaso’s total revenue. The transaction, valued at up to $800,000, will allow Vaso to invest in its other business lines and strategic initiatives, while providing a promising future for VasoHealthcare IT under Nanox.
Spark’s Take on VASO Stock
According to Spark, TipRanks’ AI Analyst, VASO is a Neutral.
Vaso’s overall stock score is driven primarily by its stable financial performance and attractive valuation. The stock’s positive technical indicators are tempered by overbought signals, suggesting caution. The lack of earnings call and corporate events data limits additional insights.
To see Spark’s full report on VASO stock, click here.
More about Vaso
Vaso Corporation, headquartered in Plainview, New York, is a diversified MedTech company with three core businesses: VasoHealthcare, which provides professional sales services for GEHealthCare’s diagnostic imaging and ultrasound products; VasoTechnology, a leader in information technology and managed connectivity for healthcare and other sectors; and VasoMedical, which designs and manufactures proprietary medical devices, including the Biox series and the ARCS cloud-based SaaS platform.
Average Trading Volume: 143,849
Technical Sentiment Signal: Strong Buy
Current Market Cap: $30.18M
For an in-depth examination of VASO stock, go to TipRanks’ Overview page.